

Today's Notes:

- 1. Senesco Technologies**
- 2. Neuralstem's Discovery Potential**

1. SENESCO TECHNOLOGIES (SNT AMEX)

Ever since he arrived Chairman Harlan Waksal has done exactly what he said he would do. He reorganized management; cut expenses and with the help of the Board arranged the repurchase of the two toxic financings that previous management had initiated. He then raised \$12 million to push the company forward through the initial clinical trials (Phase IB/ IIA) for multiple myeloma at the Mayo Clinic.

With the overhead resistance now gone the stock is experiencing a revival. As you can see the game is on. Chairman Waksal has been unequivocally focused on making Senesco into a life science company focused specifically on cancer and more specifically on liquid tumors such as multiple myeloma, lymphoma and leukemia – initially. He is singularly focused and we think this is a recipe for success. Pre clinical test on cancer have been extremely successful. The discovery of hypusine (no one knew about hypusine before Senesco's discovery of it) is highly significant in cancer treatment. I have followed the stock and the company for 6 years now. This is what world class discovery is all about. It is time to be positioned in the company right now if you seek the comfort of the potential of a cure in the cancer field.



But you must also remember that the technology is already successfully implemented in the agricultural field with names like Bayer, Monsanto and Rahan Meristem. We think there is tremendous potential for the spin off and IPO of the agriculture business and other applications as well. Naturally if cancer trials are successful the results will quickly be accreted into the share price. So far – so good. I own shares in Senesco Technologies

2. NEURALSTEM (CUR AMEX)

Up 10% yesterday the shares just want to go higher. Neuralstem is another company that we have been extremely patient with. First public in December 2006, management has been very thorough in their science and financing of the progress therein. The patented regenerative neural stem cell technology is in the clinic. They began treating ALS patients on January 20, 2010 at Emory University in Atlanta. In December 2009 The Company said,

“Neuralstem, Inc. (NYSE Amex: CUR) today announced that its Phase I trial to treat Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig’s disease) with its spinal cord stem cells has been approved by the Institutional Review Board (IRB) at Emory University in Atlanta, GA. The trial, which was approved by the FDA in September, will take place at the Emory ALS Center, under the direction of Dr. Jonathan Glass M.D., Director of the Emory ALS Center, who will serve as the site Principal Investigator (PI).

The trial will study the safety of Neuralstem’s cells and the surgical procedures and devices required for multiple injections of Neuralstem’s cells directly into the grey matter of the spinal cord. The Emory ALS Center has posted the relevant trial information for patients on its website at <http://www.neurology.emory.edu/ALS/Stem%20Cell.html>. ALS affects roughly 30,000 people in the U.S., with about 7,000 new diagnoses per year.



“The commencement of the first trial using our stem cells, and the first ALS stem cell trial in the U. S., represents a significant step in regenerative medicine,” said Richard Garr, Neuralstem CEO. “We look forward to working with the Emory ALS Center. We expect to begin treating patients with our stem cells in January. Again, patients who are interested should reach out directly to the Emory ALS Center.”

Neuralstem is most definitely a leader in the regenerative medicine field. It seems like the market is beginning to recognize this fact. We await the results from these initial tests. Please see the web site.

The material herein is for informational purposes only and is not intended to and does not constitute the rendering of investment advice or the solicitation of an offer to buy securities. The foregoing discussion contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (The Act). In particular when used in the preceding discussion the words “plan,” confident that, believe, scheduled, expect, or intend to, and similar conditional expressions are intended to identify forward-looking statements subject to the safe harbor created by the ACT. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward looking statements. Such risks and uncertainties include, but are not limited to future events and financial performance of the company which are inherently uncertain and actual events and / or results may differ materially. In addition Dr. Berry may review investments that are not registered in the U.S. He owns shares and in Goldcorp, Senesco Technologies, Horseshoe Gold, Derek Oil and Gas, Terraco Gold, Neuralstem, Piedmont Mining, MegaWest Energy, CGX Energy, Salares Lithium and Quaterra Resources. Dr. Berry is a paid advisor to Revett Minerals. We cannot attest to nor certify the correctness of any information in this note. Please consult your financial advisor and perform your own due diligence before considering any companies mentioned in this informational bulletin.